HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A correction has been published Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chamsuddin, A. A. Articles by Hunter, D. W. Search for Related Content PubMed PubMed Citation Articles by Chamsuddin, A. A. Articles by Hunter, D. W. Social Bookmarking                      What's this?

Using a Dopamine Type IA Receptor Agonist in High-Risk Patients to Ameliorate Contrast-Associated Nephropathy

¹ Department of Radiology, Cardiovascular and Interventional Radiology, University of Tennessee, 865 Jefferson Ave., Ste. 121C, Memphis, TN 38163.
² Department of Radiology, Cardiovascular and Interventional Radiology, University of Minnesota, MMC 292, 420 Delaware St. S.E., Minneapolis, MN 55455.
³ Department of Radiology, Cardiovascular and Interventional Radiology, Mayo Clinic, St. Mary's Hospital, Rm. 6-460, 1216 2nd St. S.W., Rochester, MN 55902.

OBJECTIVE. The objective of our study was to evaluate the effects of fenoldopam mesylate, a dopamine type 1A receptor agonist and a potent renal vasodilator that markedly increases renal blood flow, on kidney function of patients who were receiving iodinated contrast material for an interventional procedure and thought to be at high risk of contrast-associated nephropathy.

MATERIALS AND METHODS. We retrospectively reviewed the records of all patients who received fenoldopam mesylate to determine the acute and, when possible, the longer term effects on kidney function.

RESULTS. Twenty-nine cases were reviewed. The average serum creatinine value before contrast administration was 2.55 µg/dL (range, 1.3-5.8 µg/dL). Twenty-four hours after contrast administration, serum creatinine was measured in 28 of the 29 patients. The serum creatinine values had decreased in 16 of the 28 patients by an average of 0.55 µg/dL. In nine patients, the serum creatinine value had not changed. Two of the three increases in the serum creatinine value appear to have been caused primarily by problems that did not involve the contrast material.

CONCLUSION. The use of fenoldopam mesylate at appropriate doses offers patients at high risk for contrast-associated nephropathy a chance to avoid this complication. To learn the extent and true nature of the effect of fenoldopam mesylate in this patient population requires a rigorous scientific trial, which is currently underway.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. G. Gleeson and S. Bulugahapitiya Contrast-Induced Nephropathy Am. J. Roentgenol., December 1, 2004; 183(6): 1673 - 1689. [Full Text] [PDF]

				C. D. Cox and J. P. Tsikouris Preventing Contrast Nephropathy: What Is the Best Strategy? A Review of the Literature J. Clin. Pharmacol., April 1, 2004; 44(4): 327 - 337. [Abstract] [Full Text] [PDF]

				J. B. Ashley and S. F. Millward Contrast Agent-Induced Nephropathy: A Simple Way to Identify Patients with Preexisting Renal Insufficiency Am. J. Roentgenol., August 1, 2003; 181(2): 451 - 454. [Full Text] [PDF]

				E. J. Thompson and S. L. King Acetylcysteine and Fenoldopam: Promising New Approaches for Preventing Effects of Contrast Nephrotoxicity Crit. Care Nurse, June 1, 2003; 23(3): 39 - 46. [Full Text] [PDF]